Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA
NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and
commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Company has initiated the submission of its Biologics License Application
(“BLA”) for omburtamab under the U.S. Food and Drug Administration’s (“FDA”) Rolling Review process. Omburtamab is an investigational, monoclonal antibody that targets B7-H3, an immune checkpoint
molecule that is widely expressed in tumor cells of several cancer types. The omburtamab BLA is for the treatment of pediatric patients with CNS/leptomeningeal metastases from neuroblastoma.
Lesen Sie auch
The non-clinical portion and a part of the CMC portion of the rolling BLA were submitted during June 2020, and completion of the BLA submission is currently expected to take place over the next
four to six weeks. The clinical submission will be based on the safety and efficacy results of the pivotal Phase 2 studies 101 and 03-133, which the Company expects to present later this
year.
“As the father of a long-term high-risk neuroblastoma survivor with CNS/Leptomeningel metastasis, I know how important this potentially is for families faced with brain metastasis from high-risk
neuroblastoma and I am excited to see the initiation of Y-mAbs’ second BLA submission this year in neuroblastoma. We believe this is a key milestone for families facing CNS/leptomeningeal
metastases from neuroblastoma and for Y-mAbs. We are very grateful to all clinical sites involved in developing omburtamab, and especially to our employees in the development team.” stated Thomas
Gad, Founder, Chairman and President.